Compare CALC & BIOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CALC | BIOT |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6M | 6.6M |
| IPO Year | 2020 | N/A |
| Metric | CALC | BIOT |
|---|---|---|
| Price | $1.52 | $0.18 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $38.00 | N/A |
| AVG Volume (30 Days) | 66.1K | ★ 346.0K |
| Earning Date | 11-24-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.44 | $0.17 |
| 52 Week High | $72.00 | $50.00 |
| Indicator | CALC | BIOT |
|---|---|---|
| Relative Strength Index (RSI) | 50.78 | 16.31 |
| Support Level | $1.00 | $0.17 |
| Resistance Level | $1.84 | $0.40 |
| Average True Range (ATR) | 0.21 | 0.02 |
| MACD | 0.06 | 0.03 |
| Stochastic Oscillator | 54.93 | 24.75 |
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.
Instinct Bio Technical Company Holdings Inc is a Cayman Islands-based vertically integrated group engaged in the research and development, manufacturing, branding, and distribution of stem cells, regenerative medicine, wellness, and beauty as its core areas. Its product portfolio includes stem cell-derived serums and skincare formulations for aesthetic and dermatological applications. The company also develops regenerative products for skin healing, hydration, and elasticity.